



Kent Academic Repository

Zhou, Jiandong, Lee, Sharen, Lakhani, Ishan, Yang, Lei, Liu, Tong, Zhang, Yuhui, Xia, Yunlong, Wong, Wing Tak, Bao, Kelvin King Hei, Wong, Ian Chi Kei and others (2022) *Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis*. *Cardio-Oncology*, 8 (1). ISSN 2057-3804.

Downloaded from

<https://kar.kent.ac.uk/98719/> The University of Kent's Academic Repository KAR

The version of record is available from

<https://doi.org/10.1186/s40959-021-00128-5>

This document version

Publisher pdf

DOI for this version

Licence for this version

CC BY (Attribution)

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

RESEARCH

Open Access



Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis

Jiandong Zhou^{1,2†}, Sharen Lee^{2†}, Ishan Lakhani², Lei Yang³, Tong Liu³, Yuhui Zhang⁴, Yunlong Xia⁵, Wing Tak Wong⁶, Kelvin King Hei Bao⁷, Ian Chi Kei Wong⁸, Gary Tse^{2,3,9*} and Qingpeng Zhang^{1,10*}

Abstract

Background: Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major classes of immune checkpoint inhibitors that are increasingly used for cancer treatment. However, their use is associated with adverse cardiovascular events. We examined the incidence of new-onset cardiac complications in patients receiving PD-1 or PD-L1 inhibitors.

Methods: Patients receiving PD-1 or PD-L1 inhibitors since their launch up to 31st December 2019 at publicly funded hospitals of Hong Kong, China, without pre-existing cardiac complications were included. The primary outcome was a composite of incident heart failure, acute myocardial infarction, atrial fibrillation, or atrial flutter with the last follow-up date of 31st December 2020. Propensity score matching between PD-L1 inhibitor use and PD-1 inhibitor use with a 1:2 ratio for patient demographics, past comorbidities and non-PD-1/PD-L1 medications was performed with nearest neighbour search strategy (0.1 caliper). Univariable and multivariable Cox regression analysis models were conducted. Competing risks models and multiple propensity matching approaches were considered for sensitivity analysis.

Results: A total of 1959 patients were included. Over a median follow-up of 247 days (interquartile range [IQR]: 72-506), 320 (incidence rate [IR]: 16.31%) patients met the primary outcome after PD-1/PD-L1 treatment: 244 (IR: 12.57%) with heart failure, 38 (IR: 1.93%) with acute myocardial infarction, 54 (IR: 2.75%) with atrial fibrillation, 6 (IR: 0.31%) with atrial flutter. Compared with PD-1 inhibitor treatment, PD-L1 inhibitor treatment was significantly

*Correspondence: garytse86@gmail.com; qingpeng.zhang@cityu.edu.hk

†Jiandong Zhou and Sharen Lee are joint first author.

³Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, 300211 Tianjin, China

¹⁰School of Data Science, City University of Hong Kong, Hong Kong, China

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

associated with lower risks of the composite outcome both before (hazard ratio [HR]: 0.32, 95% CI: [0.18-0.59], P value=0.0002) and after matching (HR: 0.34, 95% CI: [0.18-0.65], P value=0.001), and lower all-cause mortality risks before matching (HR: 0.77, 95% CI: [0.64-0.93], P value=0.0078) and after matching (HR: 0.80, 95% CI: [0.65-1.00], P value=0.0463). Patients who developed cardiac complications had shorter average readmission intervals and a higher number of hospitalizations after treatment with PD-1/PD-L1 inhibitors in both the unmatched and matched cohorts (P value<0.0001). Multivariable Cox regression models, competing risk analysis with cause-specific and subdistribution hazard models, and multiple propensity approaches confirmed these observations.

Conclusions: Compared with PD-1 treatment, PD-L1 treatment was significantly associated with lower risk of new onset cardiac complications and all-cause mortality both before and after propensity score matching.

Introduction

The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway is one of the major immune checkpoints for mitigating the immune response to prevent autoimmunity. The T-cell mediated pathway for cancer detection requires coinhibitory signal, in addition to the binding of T cell receptor on T cells. PD-1 and PD-L1, one of the best characterized co-inhibitory signaling pathway, control the magnitude and duration of response against autoimmunity [1]. However, cancer cells often devise strategies to hijack these mechanisms to evade anti-tumor immunity. In this regard, inhibitors of PD-1 (e.g., pembrolizumab, nivolumab, cemiplimab) and PD-L1 (e.g., atezolizumab, avelumab, durvalumab) have shown clinical efficacies against different types of solid tumors, including melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma and bladder cancer. Pembrolizumab is also the first agent to receive a “pan-cancer” approval by the United States Food and Drug Administration (FDA) for the treatment of unresectable or metastatic solid tumors that have high microsatellite instability or mismatch repair deficiency.

Despite their treatment efficacy in clinical oncology, immune-related adverse events associated with the use of immune checkpoint inhibitors (ICIs) are now increasingly recognized [2–5]. Adverse events include atherosclerosis, colitis, hepatitis, adrenocorticotropic hormone insufficiency, hypothyroidism, type 1 diabetes mellitus, and acute kidney injury [6–8]. To this end, cardiovascular complications are estimated to constitute approximately 2% of ICI-related adverse drug reactions [9]. The commonest is myocarditis, but other cardiovascular abnormalities reported are left ventricular dysfunction, acute myocardial infarction (AMI), cardiac arrhythmias and heart failure [10]. These cardiovascular complications typically present with clinical heterogeneity, and in turn account for the high morbidity and mortality rates observed in such patient cohorts. Whilst cardiotoxicity is being documented with an increasing frequency, their cumulative incidence rates remain largely unexplored. In this territory-wide study, we examined the incidence

of cardiovascular events of incident heart failure, acute myocardial infarction, atrial fibrillation, or atrial flutter in cancer patients receiving PD-1 or PD-L1 inhibitors.

Methods

Study Population

This study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee. Patients receiving PD-1 or PD-L1 inhibitors since their launch up to 31st December 2020 at publicly funded hospitals or their associated outpatient/ambulatory care facilities, without pre-existing cardiac complications (including heart failure, myocardial infarction, atrial fibrillation, and atrial flutter) were included. Patient data were obtained using the electronic health record database, which is connected to the territory-wide Clinical Data Analysis and Reporting System (CDARS). The system is an integrative centralized platform that permits the extraction of clinical data for analysis and reporting. The system attributes each patient a unique reference identification number, allowing for the retrieval of comprehensive medical records, including disease diagnoses, clinical comorbidities, laboratory parameters and operative procedures. Patients or the public were not involved in any aspect of this study. The system has been previously used by both our team and other teams in Hong Kong [11–13].

Patient Data

The following clinical data were extracted: patient characteristics, including demographic details (baseline age and gender), specific pre-existing comorbidities before drug prescriptions, laboratory examinations (including complete blood counts, biochemical tests, lipid/glycemic profiles) were extracted. Past comorbidities from January 1st, 2013, to December 31st, 2020, were extracted, and categorized into hypertension, liver diseases, hip fractures/accident falls, renal diseases, diabetes mellitus, malignant dysrhythmia, chronic obstructive pulmonary disease, ischemic heart disease, peripheral vascular disease, endocrine diseases, gastrointestinal diseases, and

stroke/transient ischemic attack. The International Classification of Disease, Ninth Edition (ICD-9) codes that were used to extract the specific comorbidities and outcomes are included in Supplementary Table 2. The overall dosage and the duration of exposure to PD-L1 and PD-1 inhibitors for patients with new-onset cardiac complications are reported.

Primary outcomes on follow-up

The primary outcome was a composite of incident heart failure, acute myocardial infarction, atrial fibrillation, and atrial flutter. The follow-up period was defined as the first PD-1/PD-L1 prescription date until the primary endpoint or death occurred, or until the end date of August 31st, 2020, whichever was earlier.

Statistical analysis

Continuous variables were presented as median (95% confidence interval [CI] or interquartile range [IQR]) and categorical variables were presented as count (%). The Mann-Whitney U test was used to compare continuous variables. The χ^2 test with Yates' correction was used for 2×2 contingency data, and Pearson's χ^2 test was used for contingency data for variables with more than two categories. The patients with PD-L1 were matched with PD1 controls through propensity score matching of 1:2 ratio, based on patient demographics, Charlson's standard comorbidity index, past comorbidities, and non-PD-1/PD-L1 medications. Negligible post-weighting intergroup standardized mean difference (SMD) was defined as $SMD < 0.2$. To identify the important predictors associated with new-onset cardiac complications of patients after PD-1/PD-L1 treatment, univariable Cox regression was used to calculate hazard ratios (HRs) and 95% CIs. In addition to propensity score matching, the following approaches based on the propensity scores were employed: propensity score stratification [14], inverse probability weighting [15], and high-dimensional propensity score adjustment [16]. Paired hospitalization characteristics of patients before and after treatment were compared both in the unmatched and matched cohorts. A two-sided α of < 0.05 was considered statistically significant. Statistical analyses were performed using RStudio software (Version: 1.1.456) and Python (Version: 3.6).

Results

Baseline characteristics

Initially, 2426 cancer patients receiving PD-1/PD-L1 inhibitors were identified (Fig. 1). In total 1959 patients remained in the study cohort after excluding 433 patients with prior cardiac complications and 34 patients who received both PD1 and PDL1 treatments. Propensity score matching with 1:2 ratio between PD-1 and PD-L1

inhibitor use based on demographics, Charlson's standard comorbidity index, prior comorbidities, and non-PD-1/PD-L1 medications was performed. This yielded a matched cohort of 663 patients (Table 1).

Propensity score matching in 1:2 ratio between PD-1 users and PD-L1 users using the nearest neighbor search strategy (caliper as 0.1) was used. The results of logistics regression for potential confounders used in propensity score calculations, balance between groups, and estimations of bootstrapped standard error are shown in Supplementary Tables 3, 4 and 5, respectively. Distributions of propensity scores before and after matching are shown in Supplementary Fig. 1. These results indicate that the covariables between the groups are balanced after matching.


Adverse cardiovascular outcomes on follow-up and their significant predictors

In the matched cohort, 425 (IR: 64.10%) patients died and 91 (IR: 13.72%) developed new onset cardiac composite outcome. Amongst the latter, 75 (IR: 11.31%) developed heart failure, 8 (IR: 1.20%) developed acute myocardial infarction, 8 (IR: 1.20%) developed atrial fibrillation and 2 (IR: 0.30%) developed atrial flutter. The incidence rate of the composite outcome was lower in the PD-L1 cohort than in the PD-1 cohort (7.0% vs. 20.7%; $P < 0.001$).

In the 221 PD-L1 users, there were 11 patients (IR: 4.97%) who developed the composite outcome, in which 10 (IR: 4.52%) with heart failure, 1 (0.45%) with atrial fibrillation, but none with acute myocardial infarction or atrial flutter. In the 442 patients PD-1 users, 80 patients (IR: 18.09%) developed the composite outcome. Of the latter group, 65 (IR: 14.70%) developed heart failure, 8 (IR: 1.80%) developed acute myocardial infarction, 7 (IR: 1.58%) developed atrial fibrillation, and 2 (IR: 0.45%) developed atrial flutter.

The breakdown on the individual adverse events is shown in Fig. 1 and the patient characteristics stratified by adverse cardiovascular outcomes are shown in Tables 2 and 3. The cumulative incidence curves of new onset cardiac complications and all-cause mortality in cancer patients stratified by PD-1 or PD-L1 inhibitor use before and after 1:2 propensity score matching were presented in Figs. 2 and 3, respectively. The baseline characteristics of the cohort stratified by mortality status are shown in Supplementary Table 6.

Univariable Cox regression identified significant predictors of the primary composite outcome and all-cause mortality before and after propensity score matching (Table 3). Compared with PD-1 inhibitor treatment, PD-L1 inhibitor treatment was significantly associated with a lower risk of composite outcome both before (hazard ratio [HR]: 0.32, 95% CI: [0.18-0.59], P



value=0.0002***) and after matching (HR: 0.34, 95% CI: [0.18-0.65], P value=0.001**), and lower all-cause mortality risk before matching (HR: 0.77, 95% CI: [0.64-0.93], P value=0.0078**) and after matching (HR: 0.80, 95% CI: [0.65-1.00], P value=0.0463).

More PD-L1 expenditure (HR:1.000; 95% CI: 1.000-1.000; P value=0.0528), shorter PD-L1 inhibitors duration (HR:0.99; 95% CI: 0.99-1.00; P value=0.0263*), more

PD-1 expenditure, HKD (HR:1.000; 95% CI: 1.000-1.001; P value=0.0018**), and shorter PD-1 inhibitors duration (HR:0.998; 95% CI: 0.997-0.999; P value=0.0007***) were associated with new onset cardiac composite outcome in the matched cohort. Significant laboratory examinations significantly associated with new onset cardiac composite outcome include higher levels of mean corpuscular volume (HR:1.03; 95% CI: 1.00-1.07; P value=0.0470*),

Table 1 Clinical characteristics of patients with PD-1 use and PD-L1 use before and after 1:2 propensity score matching

Characteristics	Before matching		After 1:2 matching		SMD	PD-1 users (N=442) Mean(SD);n or Count(%)	SMD
	All (N = 1959) Mean(SD);N or Count(%)	PD-L1 users (N=221) Mean(SD);N or Count(%)	All (N = 663) Mean(SD);N or Count(%)	PD-L1 users (N = 221) Mean(SD);N or Count(%)			
Adverse events							
All-cause mortality	1319(67.33%)	115(52.03%)	425(64.10%)	115(52.03%)	0.36 ^a	310(70.13%)	0.38 ^a
Composite outcome	320(16.33%)	11(4.97%)	91(13.72%)	11(4.97%)	0.41 ^a	80(18.09%)	0.42 ^a
Heart failure	244(12.45%)	10(4.52%)	75(11.31%)	10(4.52%)	0.32 ^a	65(14.70%)	0.35 ^a
Acute myocardial infarction	38(1.93%)	0(0.00%)	8(1.20%)	0(0.00%)	0.21 ^a	8(1.80%)	0.19
Atrial fibrillation	54(2.75%)	1(0.45%)	8(1.20%)	1(0.45%)	0.2	7(1.58%)	0.11
Atrial flutter	6(0.30%)	0(0.00%)	2(0.30%)	0(0.00%)	0.08	2(0.45%)	0.1
Demographics							
Male gender	1341(68.45%)	165(74.66%)	498(75.11%)	165(74.66%)	0.15	333(75.33%)	0.02
Female gender	618(31.54%)	56(25.33%)	165(24.88%)	56(25.33%)	0.15	109(24.66%)	0.02
Baseline age, years	61.0(13.7);n = 1959	63.1(10.2);n = 221	63.0(10.2);n = 663	63.1(10.2);n = 221	0.19	63.0(10.1);n = 442	0
<40	151(7.70%)	7(3.16%)	20(3.01%)	7(3.16%)	0.22 ^a	13(2.94%)	0.01
[40, 50)	194(9.90%)	13(5.88%)	43(6.48%)	13(5.88%)	0.17	30(6.78%)	0.04
[50-60)	481(24.55%)	51(23.07%)	155(23.37%)	51(23.07%)	0.04	104(23.52%)	0.01
[60-70)	631(32.21%)	96(43.43%)	288(43.43%)	96(43.43%)	0.26 ^a	192(43.43%)	0
[70-80)	391(19.95%)	48(21.71%)	133(20.06%)	48(21.71%)	0.05	85(19.23%)	0.06
>=80	111(5.66%)	6(2.71%)	24(3.61%)	6(2.71%)	0.16	18(4.07%)	0.08
Past comorbidities							
Charlson's standard comorbidity index	6.1(3.3);n = 1959	6.5(3.1);n = 221	6.5(3.1);n = 663	6.5(3.1);n = 221	0.16	6.48(3.08);n = 442	0.02
Hypertension	256(13.06%)	29(13.12%)	88(13.27%)	29(13.12%)	0	59(13.34%)	0.01
Liver diseases	193(9.85%)	8(3.61%)	24(3.61%)	8(3.61%)	0.28 ^a	16(3.61%)	0
Hip fractures/accident falls	77(3.93%)	13(5.88%)	37(5.58%)	13(5.88%)	0.1	24(5.42%)	0.02
Renal diseases	292(14.90%)	29(13.12%)	85(12.82%)	29(13.12%)	0.06	56(12.66%)	0.01
Diabetes mellitus	156(7.96%)	20(9.04%)	60(9.04%)	20(9.04%)	0.04	40(9.04%)	0
Malignant dysrhythmia	12(0.61%)	0(0.00%)	2(0.30%)	0(0.00%)	0.12	2(0.45%)	0.1
Chronic obstructive pulmonary disease	15(0.76%)	2(0.90%)	6(0.90%)	2(0.90%)	0.02	4(0.90%)	0
Ischemic heart disease	61(3.11%)	5(2.26%)	15(2.26%)	5(2.26%)	0.06	10(2.26%)	0
Peripheral vascular disease	11(0.56%)	1(0.45%)	3(0.45%)	1(0.45%)	0.02	2(0.45%)	0
Endocrine diseases	548(27.97%)	56(25.33%)	166(25.03%)	56(25.33%)	0.07	110(24.88%)	0.01

Table 1 (continued)

Characteristics	Before matching		After 1:2 matching		SMD	SMD
	All (N = 1959)	PD-1 users (N = 221)	All (N = 663)	PD-1 users (N = 221)		
	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)		
Gastrointestinal diseases	1412(72.07%)	184(83.25%)	1228(70.65%)	184(83.25%)	3.67(83.03%)	0.01
Stroke/transient ischemic attack	80(4.08%)	8(3.61%)	72(4.14%)	8(3.61%)	16(3.61%)	0
Hospitalization						
Average readmission	68.5(194.8);n = 1876	53.3(112.0);n = 215	70.5(203.0);n = 1661	53.3(112.0);n = 215	71.3(234.5);n = 432	0.1
Total episode number	14.2(13.9);n = 1876	12.2(8.9);n = 215	14.5(14.4);n = 1661	12.2(8.9);n = 215	14.6(11.7);n = 432	0.22 ^a
Overall hospital stay, days	35.2(38.2);n = 1876	25.5(22.4);n = 215	36.5(39.6);n = 1661	25.5(22.4);n = 215	36.7(34.4);n = 432	0.39 ^a
Medications						
PD-L1 expenditure, HKD	98251.0(98697.8);n = 221	98251.0(98697.8);n = 221	-	98251.0(98697.8);n = 221	-	-
Total PD-L1 dose amount, mg	12644.1(27488.6);n = 221	12644.1(27488.6);n = 221	-	12644.1(27488.6);n = 221	-	-
PD-L1 inhibitors duration, days	176.0(200.9);n = 221	176.0(200.9);n = 221	-	176.0(200.9);n = 221	-	-
PD-1 expenditure, HKD	193878.8(291968.7);n = 1750	1750	192915.5(291869.7);n = 1738	203782.5(259059.2);n = 454	200263.3(257787.4);n = 442	-
Total PD-1 dose amount (mg)	2817.9(10492.2);n = 1750	-	2827.3(10527.4);n = 1738	2454.7(5152.0);n = 454	2482.0(5216.3);n = 442	-
PD-1 inhibitors duration, days	202.7(237.7);n = 1750	-	201.5(237.0);n = 1738	207.7(234.7);n = 454	202.9(232.1);n = 442	-
Anticoagulants	1108(56.55%)	120(54.29%)	988(56.84%)	362(54.60%)	242(54.75%)	0.01
Steroids	1108(56.55%)	120(54.29%)	988(56.84%)	362(54.60%)	242(54.75%)	0.01
biomarkers						
Neutrophil-to-lymphocyte ratio	4.6(6.4);n = 1952	4.5(9.5);n = 221	4.6(5.9);n = 1731	4.3(6.5);n = 663	4.2(4.2);n = 442	0.04
Platelet-to-lymphocyte ratio	212.3(243.9);n = 1953	203.9(188.4);n = 221	213.4(250.1);n = 1732	210.2(304.3);n = 663	213.3(348.3);n = 442	0.03
Aspartate transaminase-to-alanine transaminase ratio	1.8(3.6);n = 1308	1.1(0.5);n = 128	1.9(3.8);n = 1180	1.5(2.1);n = 405	1.7(2.4);n = 277	0.32 ^a
Triglyceride glucose index	7.1(0.6);n = 580	7.07(0.65);n = 67	7.06(0.62);n = 513	7.0(0.6);n = 207	7.0(0.6);n = 140	0.07
Urea-to-creatinine ratio	73.1(40.8);n = 1937	68.3(23.3);n = 221	73.8(42.4);n = 1716	69.5(29.2);n = 659	70.1(31.8);n = 438	0.07

Table 1 (continued)

Characteristics	Before matching		After 1:2 matching		SMD	
	All (N = 1959)	PD-1 users (N = 221)	All (N = 663)	PD-1 users (N = 221)		
	Mean(SD);n or Count(%)	Mean(SD);n or Count(%)	Mean(SD);n or Count(%)	Mean(SD);n or Count(%)	PD-1 users (N = 442)	
Monocyte-to-lymphocyte ratio	0.4(0.5);n = 1950	0.4(0.5);n = 221	0.4(0.4);n = 662	0.4(0.5);n = 221	0.5(0.4);n = 441	0.04
Complete blood counts						
Mean corpuscular volume, fL	88.0(8.2);n = 1953	88.4(7.7);n = 221	88.2(7.7);n = 663	88.4(7.7);n = 221	88.1(7.8);n = 442	0.04
Eosinophil, x10 ⁹ /L	0.2(0.3);n = 1952	0.2(0.32);n = 221	0.2(0.3);n = 663	0.2(0.32);n = 221	0.21(0.24);n = 442	0.03
Lymphocyte, x10 ⁹ /L	1.5(0.9);n = 1953	1.5(0.9);n = 221	1.5(0.7);n = 663	1.6(0.8);n = 221	1.5(0.7);n = 442	0.21 ^a
Metamyelocyte, x10 ⁹ /L	0.8(5.0);n = 225	0.5(0.7);n = 13	0.3(0.5);n = 72	0.5(0.7);n = 13	0.3(0.4);n = 59	0.37 ^a
Monocyte, x10 ⁹ /L	0.5(0.3);n = 1953	0.54(0.25);n = 221	0.5(0.3);n = 663	0.54(0.25);n = 221	0.55(0.32);n = 442	0.03
Neutrophil, x10 ⁹ /L	5.1(3.3);n = 1953	5.2(3.4);n = 221	5.0(3.2);n = 663	5.2(3.4);n = 221	4.9(3.1);n = 442	0.09
White blood count, x10 ⁹ /L	7.4(5.5);n = 1953	7.43(3.3);n = 221	7.3(3.6);n = 663	7.4(3.3);n = 221	7.3(3.8);n = 442	0.04
Mean cell haemoglobin, pg	30.7(3.3);n = 1953	30.72(3.29);n = 221	30.8(3.2);n = 663	30.7(3.3);n = 221	30.8(3.1);n = 442	0.02
Myelocyte, x10 ⁹ /L	0.8(3.1);n = 328	1.0(2.0);n = 26	0.6(1.5);n = 97	1.0(2.0);n = 26	0.5(1.2);n = 71	0.26 ^a
Platelet, x10 ⁹ /L	247.9(108.5);n = 1953	261.5(92.6);n = 221	252.6(98.9);n = 663	261.5(92.6);n = 221	248.2(101.7);n = 442	0.14
Red blood count, x10 ¹² /L	4.4(0.7);n = 1953	4.4(0.7);n = 221	4.5(0.7);n = 663	4.6(0.6);n = 221	4.4(0.7);n = 442	0.21 ^a
Hematocrit, L/L	0.4(0.1);n = 1895	0.4(0.05);n = 208	0.4(0.1);n = 626	0.4(0.05);n = 208	0.39(0.05);n = 418	0.28 ^a
Renal and liver functions						
Potassium, mmol/L	4.1(0.4);n = 1941	4.14(0.43);n = 221	4.1(0.4);n = 661	4.14(0.43);n = 221	4.13(0.42);n = 440	0.03
Urate, mmol/L	0.3(0.1);n = 627	0.33(0.1);n = 43	0.3(0.1);n = 186	0.33(0.1);n = 43	0.34(0.13);n = 143	0.07
Albumin, g/L	39.2(5.9);n = 1939	39.8(5.4);n = 220	39.5(5.4);n = 660	39.8(5.4);n = 220	39.4(5.4);n = 440	0.06
Sodium, mmol/L	139.1(3.8);n = 1941	139.4(3.1);n = 221	139.2(3.4);n = 661	139.4(3.1);n = 221	139.2(3.6);n = 440	0.07
Urea, mmol/L	5.5(2.4);n = 1937	5.3(1.8);n = 221	5.3(1.8);n = 659	5.31(1.76);n = 221	5.31(1.83);n = 438	0
Protein, g/L	72.1(12.8);n = 1853	71.3(16.3);n = 207	71.7(14.4);n = 624	71.3(16.3);n = 207	71.9(13.5);n = 417	0.04
Bilirubin, umol/L	13.0(25.3);n = 1941	9.5(6.1);n = 221	11.3(19.1);n = 661	9.5(6.1);n = 221	12.2(22.9);n = 440	0.16
Creatinine, umol/L	84.9(62.4);n = 1952	83.0(37.0);n = 221	84.8(64.0);n = 662	83.0(37.0);n = 221	85.7(74.0);n = 441	0.05
SD of creatinine	35.5(103.7);n = 1942	29.8(93.9);n = 220	29.7(82.3);n = 658	29.8(93.9);n = 220	29.7(75.9);n = 438	0
Aspartate transaminase, U/L	54.4(104.9);n = 1371	28.3(21.8);n = 142	41.2(67.2);n = 443	28.3(21.8);n = 142	47.3(79.5);n = 301	0.33 ^a
SD of aspartate transaminase	59.6(189.6);n = 1250	28.6(101.7);n = 122	36.5(84.3);n = 409	28.6(101.7);n = 122	39.8(75.6);n = 287	0.13

Table 1 (continued)

Characteristics	Before matching		After 1:2 matching		SMD	
	All (N = 1959)	PD-L1 users (N = 221)	All (N = 663)	PD-L1 users (N = 221)		
	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	PD-1 users (N = 442)	
Alkaline phosphatase, U/L	108.6(111.6);n = 1941	85.2(36.4);n = 221	102.1(99.9);n = 661	85.2(36.4);n = 221	110.5(118.9);n = 440	0.29 ^a
SD of alkaline phosphatase	64.8(95.1);n = 1928	39.6(75.3);n = 220	58.3(89.9);n = 655	39.6(75.3);n = 220	67.7(95.2);n = 435	0.33 ^a
Alanine transaminase, U/L	36.6(55.7);n = 1876	28.2(25.1);n = 207	31.4(29.5);n = 623	28.2(25.1);n = 207	33.1(31.4);n = 416	0.17
SD of alanine transaminase	36.4(84.7);n = 1855	22.9(50.7);n = 201	28.2(51.6);n = 612	22.9(50.7);n = 201	30.8(52.0);n = 411	0.15
Lipid, iron and calcium profile						
Total iron-binding capacity, L	41.0(12.3);n = 103	39.1(11.1);n = 5	42.1(12.7);n = 22	39.1(11.1);n = 5	43.0(13.3);n = 17	0.31 ^a
VitaminB12, pmol/L	453.2(327.2);n = 49	447.7(265.6);n = 3	401.2(305.7);n = 17	447.7(265.6);n = 3	391.2(321.8);n = 14	0.19
Folate, ng/mL	21.7(10.2);n = 69	16.0(3.7);n = 3	20.4(10.4);n = 19	16.0(3.7);n = 3	21.3(11.1);n = 16	0.64 ^a
Ferritin, pmol/L	2546.7(4740.6);n = 86	728.2(816.5);n = 8	194.1(2987.1);n = 22	728.2(816.5);n = 8	2634.2(3554.1);n = 14	0.74 ^a
Calcium, mmol/L	2.3(0.2);n = 1081	2.32(0.13);n = 82	2.3(0.1);n = 340	2.32(0.13);n = 82	2.33(0.15);n = 258	0.04
SD of calcium	0.1(0.1);n = 987	0.07(0.04);n = 73	0.1(0.1);n = 314	0.07(0.04);n = 73	0.1(0.07);n = 241	0.43 ^a
Phosphate, mmol/L	1.1(0.2);n = 948	1.06(0.22);n = 887	1.1(0.2);n = 286	1.08(0.18);n = 61	1.06(0.2);n = 225	0.1
SD of phosphate	0.2(0.1);n = 785	0.1(0.1);n = 44	0.2(0.1);n = 241	0.1(0.1);n = 44	0.2(0.1);n = 197	0.37 ^a
Glycemic and clotting profile						
Triglyceride, mmol/L	1.4(1.1);n = 598	1.5(1.0);n = 68	1.5(1.2);n = 214	1.5(1.05);n = 68	1.46(1.29);n = 146	0.04
SD of triglyceride	0.4(0.5);n = 294	0.4(0.43);n = 30	0.4(0.6);n = 90	0.4(0.43);n = 30	0.42(0.66);n = 60	0.04
HbA1c, g/dL	6.3(2.3);n = 1773	6.4(2.7);n = 206	6.3(2.2);n = 608	6.4(2.7);n = 206	6.2(2.0);n = 402	0.11
SD of HbA1c, g/dL	1.5(1.3);n = 1638	1.4(1.3);n = 194	1.5(1.4);n = 564	1.4(1.3);n = 194	1.6(1.4);n = 370	0.15
Glucose, mmol/L	12.8(2.0);n = 1953	13.3(1.7);n = 221	13.1(1.9);n = 663	13.3(1.7);n = 221	12.9(1.9);n = 442	0.23 ^a
SD of glucose, mmol/L	1.3(0.5);n = 1947	1.31(0.54);n = 220	1.3(0.5);n = 660	1.31(0.54);n = 220	1.32(0.51);n = 440	0.03
High sensitive troponin-I, ng/L	363.3(10967.7);n = 1141	12.7(31.8);n = 122	35.5(314.8);n = 372	12.7(31.8);n = 122	46.6(383.1);n = 250	0.12
SD of high sensitive troponin-I	124.0(1328.2);n = 755	18.2(42.4);n = 82	34.7(207.0);n = 245	18.2(42.4);n = 82	43.0(251.9);n = 163	0.14
APTT, second	30.8(5.5);n = 694	29.1(3.5);n = 46	30.4(3.9);n = 217	29.1(3.5);n = 46	30.8(3.9);n = 171	0.45 ^a
SD of APTT	2.6(3.1);n = 510	1.9(2.3);n = 26	2.1(1.8);n = 152	1.9(2.3);n = 26	2.1(1.7);n = 126	0.13
Lactate dehydrogenase, U/L	324.1(422.0);n = 1431	315.6(534.6);n = 145	302.1(354.0);n = 466	315.6(534.6);n = 145	296.0(231.0);n = 321	0.05

Table 1 (continued)

Characteristics	Before matching		PD-L1 users (N = 221)		PD-1 users (N = 1738)		After 1:2 matching		PD-L1 users (N = 221)		PD-1 users (N = 442)		SMD
	All (N = 1959)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	SMD	All (N = 663)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)	Mean(SD);N or Count(%)		
SD of lactate dehydrogenase	155.2(397.1);n = 1140	115.6(203.9);n = 102	159.1(411.1);n = 1038	0.13	121.3(206.3);n = 365	115.6(203.9);n = 102	123.6(207.6);n = 263	0.04					
Total cholesterol, mmol/L	4.6(1.1);n = 599	4.9(1.0);n = 68	4.5(1.1);n = 531	0.29 ^a	4.6(1.1);n = 214	4.9(1.0);n = 68	4.5(1.1);n = 146	0.3 ^a					
SD of total cholesterol	0.5(0.4);n = 295	0.54(0.43);n = 31	0.48(0.44);n = 264	0.14	0.5(0.5);n = 93	0.54(0.43);n = 31	0.48(0.52);n = 62	0.13					
Low-density lipoprotein, mmol/L	2.6(0.9);n = 583	2.9(0.9);n = 65	2.6(0.9);n = 518	0.34 ^a	2.7(1.0);n = 208	2.9(0.9);n = 65	2.6(1.0);n = 143	0.33 ^a					
SD of low-density lipoprotein	0.4(0.4);n = 283	0.5(0.4);n = 29	0.4(0.4);n = 254	0.18	0.4(0.4);n = 88	0.5(0.4);n = 29	0.4(0.4);n = 59	0.21 ^a					
High-density lipoprotein, mmol/L	1.3(0.4);n = 593	1.32(0.4);n = 67	1.34(0.4);n = 526	0.04	1.3(0.4);n = 212	1.32(0.4);n = 67	1.31(0.36);n = 145	0.02					
SD of high-density lipoprotein	0.1(0.1);n = 280	0.12(0.09);n = 30	0.14(0.14);n = 250	0.17	0.2(0.1);n = 87	0.1(0.1);n = 30	0.2(0.2);n = 57	0.32 ^a					

^a for SMD ≥ 0.2; SD: Standard deviation; SMD: Standard mean difference; APTT: applied partial thromboplastin test; PD-L1: programmed death 1 inhibitors; PD-1: programmed death 1 ligand inhibitors

Table 2 Clinical characteristics of patients who developed the composite outcome before and after 1:2 propensity score matching

Characteristics	Before matching		SMD	After 1:2 matching		SMD
	Composite outcome (N = 320) Mean(SD);N or Count(%)	No composite outcome (N = 1639) Mean(SD);N or Count(%)		Composite outcome (N = 91) Mean(SD);N or Count(%)	No composite outcome (N = 572) Mean(SD);N or Count(%)	
Demographics						
Male gender	219(68.43%)	1122(68.45%)	<0.01	69(75.82%)	429(75.00%)	0.02
Female gender	101(31.56%)	517(31.54%)	<0.01	22(24.17%)	143(25.00%)	0.02
Baseline age, years	64.0(12.8);n = 320	60.4(13.8);n = 1639	0.27 ^a	62.7(10.3);n = 91	63.1(10.1);n = 572	0.04
<40	16(5.00%)	135(8.23%)	0.13	4(4.39%)	16(2.79%)	0.09
[40, 50)	24(7.50%)	170(10.37%)	0.1	6(6.59%)	37(6.46%)	0.01
[50-60)	70(21.87%)	411(25.07%)	0.08	24(26.37%)	131(22.90%)	0.08
[60-70)	106(33.12%)	525(32.03%)	0.02	36(39.56%)	252(44.05%)	0.09
[70-80)	74(23.12%)	317(19.34%)	0.09	17(18.68%)	116(20.27%)	0.04
>=80	30(9.37%)	81(4.94%)	0.17	4(4.39%)	20(3.49%)	0.05
Past comorbidities						
Charlson's standard comorbidity index	6.7(3.3);n = 320	6.0(3.3);n = 1639	0.23 ^a	7.0(3.1);n = 91	6.4(3.1);n = 572	0.18
Hypertension	49(15.31%)	207(12.62%)	0.08	13(14.28%)	75(13.11%)	0.03
Liver diseases	22(6.87%)	171(10.43%)	0.13	3(3.29%)	21(3.67%)	0.02
Hip fractures/accident falls	19(5.93%)	58(3.53%)	0.11	9(9.89%)	28(4.89%)	0.19
Renal diseases	55(17.18%)	237(14.46%)	0.07	12(13.18%)	73(12.76%)	0.01
Diabetes mellitus	30(9.37%)	126(7.68%)	0.06	10(10.98%)	50(8.74%)	0.08
Malignant dysrhythmia	10(3.12%)	2(0.12%)	0.24 ^a	0(0.00%)	2(0.34%)	0.08
Chronic obstructive pulmonary disease	3(0.93%)	12(0.73%)	0.02	2(2.19%)	4(0.69%)	0.13
Ischemic heart disease	19(5.93%)	42(2.56%)	0.17	3(3.29%)	12(2.09%)	0.07
Peripheral vascular disease	3(0.93%)	8(0.48%)	0.05	1(1.09%)	2(0.34%)	0.09
Endocrine diseases	76(23.75%)	472(28.79%)	0.11	20(21.97%)	146(25.52%)	0.08
Gastrointestinal diseases	230(71.87%)	1182(72.11%)	0.01	82(90.10%)	469(81.99%)	0.24 ^a
Stroke/transient ischemic attack	17(5.31%)	63(3.84%)	0.07	3(3.29%)	21(3.67%)	0.02
Hospitalization						
Average readmission	45.2(87.1);n = 312	73.1(209.5);n = 1564	0.17	31.0(35.6);n = 90	70.9(217.1);n = 557	0.26 ^a
Total episode number	13.2(11.4);n = 312	14.4(14.4);n = 1564	0.09	14.5(9.0);n = 90	13.7(11.1);n = 557	0.08
Overall hospital stay, days	40.4(38.3);n = 312	34.2(38.1);n = 1564	0.16	44.7(34.7);n = 90	31.0(30.4);n = 557	0.42 ^a
Medications						
PD-L1 v.s. PD-1	11(3.43%)	210(12.81%)	0.35 ^a	11(12.08%)	210(36.71%)	0.60 ^a
PD-L1 expenditure, HKD	58752.6(47219.8);n = 11	100319.9(100303.8);n = 210	0.53 ^a	58752.6(47219.8);n = 11	100319.9(100303.8);n = 210	0.53 ^a

Table 2 (continued)

Characteristics	Before matching		SMD	After 1:2 matching		SMD
	Composite outcome (N = 320) Mean(SD);N or Count(%)	No composite outcome (N = 1639) Mean(SD);N or Count(%)		Composite outcome (N = 91) Mean(SD);N or Count(%)	No composite outcome (N = 572) Mean(SD);N or Count(%)	
Total PD-L1 dose amount, mg	5127.3(4650.4);n = 11	13037.9(28128.8);n = 210	0.39 ^a	5127.3(4650.4);n = 11	13037.9(28128.8);n = 210	0.39 ^a
PD-L1 inhibitors duration, days	84.6(114.7);n = 11	180.7(203.5);n = 210	0.58 ^a	84.6(114.7);n = 11	180.7(203.5);n = 210	0.58 ^a
PD-1 expenditure, HKD	163440.0(284113.0);n = 309	200406.0(293311.2);n = 1441	0.13	183754.8(224766.1);n = 80	208066.4(265897.1);n = 374	0.1
Total PD-1 dose amount (mg)	5146.2(21240.1);n = 309	2318.6(5983.5);n = 1441	0.18	3948.7(9243.4);n = 80	2135.1(3682.3);n = 374	0.26 ^a
PD-1 inhibitors duration, days	172.1(197.1);n = 309	209.3(245.1);n = 1441	0.17	173.9(197.7);n = 80	214.9(241.5);n = 374	0.19
Anticoagulants	171(53.43%)	937(57.16%)	0.08	47(51.64%)	315(55.06%)	0.07
Steroids	171(53.43%)	937(57.16%)	0.08	47(51.64%)	315(55.06%)	0.07
Biomarkers						
Neutrophil-to-lymphocyte ratio	4.3(6.8);n = 320	4.6(6.3);n = 1632	0.05	3.5(1.8);n = 91	4.4(6.9);n = 572	0.19
Platelet-to-lymphocyte ratio	209.3(237.5);n = 320	212.9(245.2);n = 1633	0.02	199.9(135.5);n = 91	211.8(323.2);n = 572	0.05
Aspartate transaminase-to-alanine transaminase ratio	1.7(1.7);n = 204	1.8(3.9);n = 1104	0.05	1.2(0.6);n = 52	1.5(2.2);n = 353	0.2
Triglyceride glucose index	6.9(0.5);n = 106	7.1(0.6);n = 474	0.35 ^a	6.8(0.5);n = 28	7.1(0.6);n = 179	0.44 ^a
Urea-to-creatinine ratio	72.9(30.7);n = 317	73.2(42.5);n = 1620	0.01	78.0(45.9);n = 91	68.1(25.3);n = 568	0.26 ^a
Monocyte-to-lymphocyte ratio	0.4(0.4);n = 319	0.5(0.5);n = 1631	0.05	0.44(0.36);n = 90	0.45(0.45);n = 572	0.03
Complete blood counts						
Hb, g/dL	12.9(1.9);n = 320	12.8(2.0);n = 1633	0.03	13.6(1.5);n = 91	13.0(1.9);n = 572	0.35 ^a
SD of Hb	1.4(0.5);n = 320	1.3(0.6);n = 1627	0.14	1.5(0.4);n = 91	1.3(0.5);n = 569	0.41 ^a
Mean corpuscular volume, fL	88.9(7.8);n = 320	87.8(8.2);n = 1633	0.13	89.9(5.1);n = 91	87.9(8.0);n = 572	0.29 ^a
Eosinophil, x10 ⁹ /L	0.18(0.2);n = 320	0.19(0.33);n = 1632	0.02	0.21(0.21);n = 91	0.2(0.27);n = 572	0.05
Lymphocyte, x10 ⁹ /L	1.6(1.0);n = 320	1.5(0.9);n = 1633	0.08	1.6(0.6);n = 91	1.5(0.7);n = 572	0.09
Metamyelocyte, x10 ⁹ /L	0.3(0.6);n = 37	0.9(5.5);n = 188	0.13	0.35(0.36);n = 11	0.34(0.53);n = 61	0.02
Monocyte, x10 ⁹ /L	0.54(0.3);n = 320	0.53(0.31);n = 1633	0.02	0.6(0.4);n = 91	0.5(0.3);n = 572	0.1
Neutrophil, x10 ⁹ /L	5.0(3.2);n = 320	5.1(3.3);n = 1633	0.02	4.99(2.76);n = 91	5.02(3.28);n = 572	0.01
White blood count, x10 ⁹ /L	7.41(3.71);n = 320	7.39(5.8);n = 1633	0	7.4(3.2);n = 91	7.3(3.7);n = 572	0.01
Mean cell haemoglobin, pg	30.9(3.2);n = 320	30.6(3.4);n = 1633	0.08	31.4(2.4);n = 91	30.7(3.3);n = 572	0.24 ^a
Myelocyte, x10 ⁹ /L	0.5(0.9);n = 50	0.8(3.3);n = 278	0.14	0.4(0.5);n = 16	0.7(1.6);n = 81	0.27 ^a

Table 2 (continued)

Characteristics	Before matching		SMD	After 1:2 matching		SMD
	Composite outcome (N = 320) Mean(SD);N or Count(%)	No composite outcome (N = 1639) Mean(SD);N or Count(%)		Composite outcome (N = 91) Mean(SD);N or Count(%)	No composite outcome (N = 572) Mean(SD);N or Count(%)	
Platelet, x10 ⁹ /L	248.7(100.8);n = 320	247.8(110.0);n = 1633	0.01	258.9(81.8);n = 91	251.6(101.4);n = 572	0.08
Red blood count, x10 ¹² /L	4.36(0.68);n = 320	4.4(0.71);n = 1633	0.06	4.54(0.51);n = 91	4.45(0.68);n = 572	0.14
Hematocrit, L/L	0.38(0.05);n = 303	0.38(0.06);n = 1592	0.02	0.41(0.04);n = 79	0.39(0.05);n = 547	0.39 ^a
Renal and liver functions						
Potassium, mmol/L	4.14(0.45);n = 318	4.12(0.43);n = 1623	0.03	4.12(0.39);n = 91	4.13(0.43);n = 570	0.02
Urate, mmol/L	0.34(0.17);n = 96	0.32(0.13);n = 531	0.14	0.33(0.19);n = 32	0.34(0.11);n = 154	0.02
Albumin, g/L	39.17(5.99);n = 318	39.2(5.89);n = 1621	0	40.4(4.3);n = 91	39.4(5.6);n = 569	0.21 ^a
Sodium, mmol/L	139.0(3.8);n = 318	139.1(3.8);n = 1623	0.03	139.2(3.6);n = 91	139.3(3.4);n = 570	0.01
Urea, mmol/L	5.7(2.8);n = 317	5.5(2.4);n = 1620	0.08	5.34(2.09);n = 91	5.3(1.76);n = 568	0.02
Protein, g/L	72.6(12.5);n = 308	72.0(12.9);n = 1545	0.04	72.2(12.5);n = 87	71.6(14.7);n = 537	0.05
Bilirubin, umol/L	11.9(16.6);n = 318	13.2(26.6);n = 1623	0.05	10.9(7.3);n = 91	11.4(20.3);n = 570	0.04
Creatinine, umol/L	84.6(44.3);n = 320	85.0(65.3);n = 1632	0.01	78.0(42.3);n = 91	85.9(66.8);n = 571	0.14
SD of creatinine	39.6(128.3);n = 319	34.7(98.1);n = 1623	0.04	28.8(55.2);n = 91	29.9(85.9);n = 567	0.01
Aspartate transaminase, U/L	45.2(56.6);n = 221	56.2(111.7);n = 1150	0.12	29.0(15.0);n = 64	43.3(72.3);n = 379	0.27 ^a
SD of aspartate transaminase	57.8(157.0);n = 198	59.9(195.2);n = 1052	0.01	30.5(74.7);n = 62	37.5(85.9);n = 347	0.09
Alkaline phosphatase, U/L	98.9(76.8);n = 318	110.5(117.1);n = 1623	0.12	87.6(42.5);n = 91	104.4(106.1);n = 570	0.21 ^a
SD of alkaline phosphatase	68.8(96.7);n = 317	64.0(94.8);n = 1611	0.05	62.9(90.6);n = 90	57.5(89.9);n = 565	0.06
Alanine transaminase, U/L	36.0(69.2);n = 301	36.7(52.8);n = 1575	0.01	26.7(16.3);n = 79	32.1(30.9);n = 544	0.22 ^a
SD of alanine transaminase	40.6(122.4);n = 300	35.6(75.3);n = 1555	0.05	21.6(21.1);n = 78	29.2(54.6);n = 534	0.18
Lipid, iron and calcium profile						
Total iron-binding capacity, L	41.4(14.2);n = 13	40.9(12.1);n = 90	0.04	61.3(15.3);n = 2	40.2(11.1);n = 20	1.58 ^a
VitaminB12, pmol/L	305.1(109.5);n = 6	473.9(342.5);n = 43	0.66 ^a	304.0(145.7);n = 2	414.1(322.1);n = 15	0.44 ^a
Folate, ng/mL	26.5(14.2);n = 8	21.1(9.5);n = 61	0.44 ^a	32.3(29.6);n = 2	19.0(6.8);n = 17	0.62 ^a
Ferritin, pmol/L	3257.7(4708.7);n = 12	2431.4(4767.6);n = 74	0.17	5116.7(6053.8);n = 2	1623.6(2601.0);n = 20	0.75 ^a
Calcium, mmol/L	2.31(0.14);n = 185	2.32(0.16);n = 896	0.06	2.34(0.1);n = 53	2.32(0.15);n = 287	0.1
SD of calcium	0.09(0.06);n = 167	0.1(0.06);n = 820	0.05	0.09(0.06);n = 48	0.09(0.07);n = 266	0.01
Phosphate, mmol/L	1.0(0.2);n = 159	1.1(0.2);n = 789	0.05	1.0(0.2);n = 41	1.1(0.2);n = 245	0.09
SD of phosphate	0.17(0.12);n = 122	0.16(0.11);n = 663	0.05	0.17(0.12);n = 33	0.15(0.09);n = 208	0.16
Glycemic and clotting profile						
Triglyceride, mmol/L	1.2(0.8);n = 110	1.5(1.1);n = 488	0.24 ^a	1.1(0.7);n = 30	1.5(1.3);n = 184	0.38 ^a

Table 2 (continued)

Characteristics	Before matching		SMD	After 1:2 matching		SMD
	Composite outcome (N = 320) Mean(SD);N or Count(%)	No composite outcome (N = 1639) Mean(SD);N or Count(%)		Composite outcome (N = 91) Mean(SD);N or Count(%)	No composite outcome (N = 572) Mean(SD);N or Count(%)	
SD of triglyceride	0.3(0.4);n = 46	0.4(0.5);n = 248	0.23 ^a	0.3(0.2);n = 8	0.4(0.6);n = 82	0.28 ^a
Glucose, mmol/L	6.2(2.1);n = 294	6.3(2.3);n = 1479	0.03	6.1(1.5);n = 86	6.3(2.3);n = 522	0.13
SD of glucose	1.55(1.26);n = 276	1.48(1.3);n = 1362	0.05	1.6(1.4);n = 83	1.5(1.4);n = 481	0.1
High sensitive troponin-I, ng/L	1660.7(24305.4);n = 232	32.2(442.8);n = 909	0.09	106.2(718.1);n = 70	19.1(50.2);n = 302	0.17
SD of high sensitive troponin-I	367.5(2445.0);n = 164	56.5(762.9);n = 591	0.17	101.3(453.4);n = 48	18.5(51.9);n = 197	0.26 ^a
APTT, second	30.4(4.2);n = 118	30.9(5.8);n = 576	0.09	30.36(3.19);n = 34	30.44(3.98);n = 183	0.02
SD of APTT	2.1(1.6);n = 79	2.7(3.3);n = 431	0.24 ^a	2.0(1.7);n = 22	2.1(1.8);n = 130	0.02
Lactate dehydrogenase, U/L	326.8(437.7);n = 247	323.6(418.8);n = 1184	0.01	273.8(128.9);n = 72	307.3(380.9);n = 394	0.12
SD of lactate dehydrogenase	133.2(228.0);n = 182	159.3(421.6);n = 958	0.08	131.0(187.3);n = 57	119.5(209.9);n = 308	0.06
Total cholesterol, mmol/L	4.4(1.0);n = 110	4.6(1.1);n = 489	0.18	4.9(1.4);n = 30	4.6(1.0);n = 184	0.24 ^a
SD of total cholesterol	0.4(0.4);n = 46	0.5(0.4);n = 249	0.15	0.7(0.9);n = 8	0.5(0.4);n = 85	0.32 ^a
Low-density lipoprotein, mmol/L	2.5(0.9);n = 109	2.6(0.9);n = 474	0.13	3.0(1.3);n = 30	2.6(0.9);n = 178	0.3 ^a
SD of low-density lipoprotein	0.38(0.35);n = 44	0.42(0.37);n = 239	0.11	0.7(0.8);n = 8	0.4(0.3);n = 80	0.45 ^a
High-density lipoprotein, mmol/L	1.4(0.4);n = 109	1.3(0.4);n = 484	0.07	1.4(0.3);n = 30	1.3(0.4);n = 182	0.26 ^a
SD of high-density lipoprotein	0.14(0.13);n = 42	0.14(0.13);n = 238	0.02	0.1(0.1);n = 8	0.2(0.1);n = 79	0.02

^a for SMD ≥ 0.2; SD: Standard deviation; SMD: Standard mean difference; APTT: applied partial thromboplastin test; PD-1: Programmed death 1 inhibitors; PD-L1: programmed death 1 ligand inhibitors

indicates the difference between patients with/without the composite outcome

hematocrit (HR:566.25; 95% CI: 4.88-65751.46; P value=0.0090**), HbA1c (HR:1.19; 95% CI: 1.05-1.34; P value=0.0072**), total cholesterol (HR:1.42; 95% CI: 1.00-2.00; P value=0.0490*), and low-density lipoprotein (HR:1.67; 95% CI: 1.14-2.45; P value=0.0091**).

In addition, greater variability in laboratory tests, including the standard deviations (SD) of alkaline phosphatase (HR:1.002; 95% CI: 1.000-1.004; P value=0.0359*), HbA1c (HR:1.94; 95% CI: 1.36-2.76; P value=0.0003***), lactate dehydrogenase (HR:1.002; 95% CI: 1.000-1.003; P value=0.0056**), and low-density lipoprotein (HR:7.64; 95% CI: 1.84-31.77; P value=0.0051**) were significantly associated with the composite outcome. The boxplots of significant measures of variability stratified by PD-1/PD-L1 inhibitor treatment in the matched cohort are shown in Fig. 4.

In addition, multivariable Cox regression models (Table 4) with multiple adjustments with significant

demographics, past comorbidities, and non-PD-L1/PD-1 drugs confirmed the protection effects of PD-L1 than PD-1 for adverse study outcomes (HR<1, P < 0.05).

Healthcare utilization before and after treatment with PD-1/PD-L1 inhibitors

Longer overall cumulative hospital stay (HR:1.01; 95% CI: 1.00-1.01; P value=0.0040**) and longer hospital stay after PD-1/PD-L1 drug use (HR:1.01; 95% CI: 1.00-1.01; P value=0.0040**) were significantly associated with the composite outcome. Furthermore, hospitalization characteristics before and after PD-1/PD-L1 treatment were compared in the subset of patients who developed the adverse outcomes, in both the unmatched and matched cohorts (Table 4). Patients who developed cardiovascular complications had a shorter average readmission interval, a higher number of hospitalizations and a longer duration of hospital stay after PD-1/PD-L1 treatment (P < 0.0001).

Table 3 Significant univariable predictors of new onset cardiac complication outcome and all-cause mortality before and after 1:2 propensity score matching

Characteristics	Before matching All-cause mortality HR [95% CI];P value	Composite outcome HR [95% CI];P value	After 1:2 matching All-cause mortality HR [95% CI];P value	Composite outcome HR [95% CI];P value
Demographics				
Male gender	0.98[0.87-1.10];0.6878	1.00[0.78-1.29];0.9898	1.03[0.83-1.29];0.7733	1.12[0.67-1.88];0.6546
Female gender	1.0[Reference]	1.0[Reference]	1.0[Reference]	1.0[Reference]
Baseline age, years	1.00[1.00-1.01];0.1533	1.01[1.01-1.02];0.0016**	1.01[1.00-1.01];0.2976	1.00[0.98-1.02];0.9421
<40	1.0[Reference]	1.0[Reference]	1.0[Reference]	1.0[Reference]
[40, 50)	1.02[0.85-1.22];0.8400	0.72[0.46-1.12];0.1450	1.07[0.73-1.56];0.7308	0.96[0.39-2.38];0.9321
[50-60)	1.04[0.92-1.18];0.5569	0.97[0.74-1.28];0.8386	0.87[0.69-1.09];0.2345	1.20[0.74-1.95];0.4528
[60-70)	1.02[0.91-1.14];0.7455	1.05[0.82-1.35];0.6880	0.98[0.81-1.19];0.8684	0.71[0.45-1.11];0.1309
[70-80)	0.98[0.85-1.12];0.7150	1.19[0.91-1.57];0.2103	1.16[0.92-1.47];0.2172	1.13[0.66-1.96];0.6528
>=80	1.07[0.86-1.35];0.5366	1.40[0.89-2.21];0.1436	1.03[0.63-1.70];0.9074	1.51[0.55-4.13];0.4210
Past comorbidities				
Charlson's standard comorbidity index	1.05[1.04-1.07];<0.0001***	1.08[1.04-1.12];<0.0001***	1.08[1.04-1.11];<0.0001***	1.07[1.00-1.15];0.0589
Hypertension	1.20[1.02-1.40];0.0262*	1.11[0.78-1.59];0.5645	1.32[1.00-1.73];0.0481*	1.18[0.61-2.29];0.6236
Liver diseases	1.24[1.04-1.47];0.0163*	0.77[0.49-1.22];0.2689	1.46[0.91-2.35];0.1148	1.32[0.42-4.18];0.6381
Hip fractures/accident falls	1.26[0.96-1.64];0.0910	1.98[1.21-3.23];0.0065**	0.79[0.50-1.25];0.3174	2.21[1.10-4.41];0.0253*
Renal diseases	1.02[0.88-1.19];0.7670	1.06[0.77-1.48];0.7155	1.05[0.79-1.39];0.7571	1.24[0.67-2.29];0.4871
Diabetes mellitus	1.13[0.92-1.37];0.2369	1.05[0.67-1.66];0.8204	1.12[0.80-1.57];0.4963	1.12[0.52-2.43];0.7733
Malignant dysrhythmia	2.09[1.12-3.89];0.0206*	11.11[5.88-20.98];<0.0001***	0.00[0.00-Inf];0.9877	0.00[0.00-Inf];0.9946
Chronic obstructive pulmonary disease	1.42[0.78-2.56];0.2515	1.83[0.59-5.72];0.2971	2.04[0.84-4.94];0.1133	5.51[1.34-22.64];0.0179*
Ischemic heart disease	0.98[0.72-1.34];0.8984	1.30[0.69-2.44];0.4160	0.98[0.49-1.98];0.9639	0.70[0.10-5.07];0.7271
Peripheral vascular disease	1.10[0.57-2.12];0.7774	1.93[0.62-6.03];0.2570	0.87[0.22-3.51];0.8502	2.51[0.35-18.07];0.3611
Endocrine diseases	1.04[0.93-1.18];0.4907	0.76[0.58-1.00];0.0538	1.04[0.84-1.29];0.7304	0.75[0.44-1.28];0.2934
Gastrointestinal diseases	1.03[0.92-1.17];0.5810	0.94[0.73-1.21];0.6327	1.22[0.93-1.59];0.1534	1.71[0.85-3.41];0.1296
Stroke/transient ischemic attack	1.11[0.85-1.46];0.4279	1.02[0.54-1.92];0.9477	1.48[0.91-2.40];0.1149	0.96[0.24-3.92];0.9586
Hospitalization				
Average readmission	1.000[1.000-1.000];0.2724	0.998[0.997-1.000];0.0625	1.000[1.000-1.001];0.0823	0.99[0.98-1.00];0.0080**
Total episode number	0.95[0.95-0.96];<0.0001***	0.96[0.95-0.97];<0.0001***	0.96[0.95-0.97];<0.0001***	0.97[0.95-0.99];0.0050**
Overall hospital stay, days	1.001[0.999-1.002];0.3779	1.001[0.999-1.004];0.3117	1.00[1.00-1.01];0.0004***	1.01[1.00-1.01];0.0040**
Medications				
PD-L1 v.s. PD-1	0.77[0.64-0.93];0.0078**	0.32[0.18-0.59];0.0002***	0.80[0.65-1.00];0.0463*	0.34[0.18-0.65];0.0010**
PD-L1 expenditure, HKD	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.000];0.0528	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.000];0.0528
Total PD-L1 dose amount, mg	1.000[1.000-1.000];0.0703	1.000[1.000-1.000];0.2410	1.000[1.000-1.000];0.0703	1.000[1.000-1.000];0.2410
PD-L1 inhibitors duration, days	1.00[0.99-1.001];<0.0001***	0.99[0.99-1.00];0.0263*	1.00[0.99-1.00];<0.0001***	0.99[0.99-1.00];0.0263*
PD-1 expenditure, HKD	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.001];0.0018**
Total PD-1 dose amount (mg)	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.000];0.1842	1.000[1.000-1.000];0.0008***	1.000[1.000-1.000];0.0958
PD-1 inhibitors duration, days	0.997[0.997-0.998];<0.0001***	0.998[0.997-0.998];<0.0001***	0.998[0.997-0.998];<0.0001***	0.998[0.997-0.999];0.0007***
Anticoagulants	0.81[0.73-0.91];0.0002***	0.73[0.58-0.93];0.0097**	0.89[0.74-1.08];0.2423	0.78[0.50-1.20];0.2574
Steroids	0.81[0.73-0.91];0.0002***	0.73[0.58-0.93];0.0097**	0.89[0.74-1.08];0.2423	0.78[0.50-1.20];0.2574

Table 3 (continued)

Characteristics	Before matching		After 1:2 matching	
	All-cause mortality HR [95% CI];P value	Composite outcome HR [95% CI];P value	All-cause mortality HR [95% CI];P value	Composite outcome HR [95% CI];P value
Biomarkers				
Neutrophil-to-lymphocyte ratio	1.01[1.00-1.01];0.0296*	1.00[0.98-1.02];0.8231	1.01[1.00-1.02];0.1025	0.97[0.92-1.03];0.3646
Platelet-to-lymphocyte ratio	1.000[1.000-1.000];0.0261*	1.000[1.000-1.001];0.5907	1.000[1.000-1.000];0.1087	1.000[0.999-1.001];0.9257
Aspartate transaminase-to-alanine transaminase ratio	1.03[1.01-1.04];<0.0001***	1.01[0.97-1.06];0.6492	1.09[1.04-1.14];0.0004***	0.96[0.71-1.29];0.7683
Triglyceride glucose index	0.97[0.83-1.13];0.6770	0.59[0.41-0.85];0.0040**	0.85[0.66-1.09];0.2061	0.55[0.30-1.02];0.0594
Urea-to-creatinine ratio	1.000[0.999-1.001];0.9657	1.000[0.997-1.002];0.9081	1.00[1.00-1.01];0.2003	1.01[1.00-1.01];0.0007***
Monocyte-to-lymphocyte ratio	1.07[0.99-1.16];0.0998	0.99[0.79-1.23];0.9303	1.20[1.02-1.43];0.0305*	1.07[0.69-1.67];0.7559
Complete blood counts				
Hb, g/dL	0.97[0.95-1.00];0.0539	1.00[0.94-1.06];0.9969	0.95[0.91-1.00];0.0543	1.19[1.05-1.34];0.0072**
SD of Hb	1.58[1.44-1.74];<0.0001***	1.51[1.23-1.85];0.0001***	1.52[1.29-1.79];<0.0001***	1.94[1.36-2.76];0.0003***
Mean corpuscular volume, fL	1.00[0.99-1.01];0.9942	1.01[1.00-1.03];0.1496	1.00[0.98-1.01];0.5845	1.03[1.00-1.07];0.0470*
Eosinophil, x10 ⁹ /L	0.74[0.58-0.93];0.0105*	0.84[0.54-1.31];0.4333	0.81[0.53-1.23];0.3143	1.14[0.49-2.64];0.7632
Lymphocyte, x10 ⁹ /L	0.98[0.92-1.05];0.6221	1.08[0.97-1.20];0.1514	0.96[0.83-1.10];0.5296	1.07[0.78-1.47];0.6699
Metamyelocyte, x10 ⁹ /L	0.87[0.70-1.07];0.1830	0.78[0.46-1.31];0.3392	0.71[0.40-1.28];0.2549	0.74[0.21-2.63];0.6383
Monocyte, x10 ⁹ /L	1.24[1.06-1.45];0.0078**	1.23[0.87-1.73];0.2362	1.51[1.14-2.00];0.0045**	1.65[0.88-3.11];0.1194
Neutrophil, x10 ⁹ /L	1.02[1.01-1.04];0.0013**	1.01[0.98-1.05];0.4025	1.03[1.01-1.06];0.0129*	1.02[0.96-1.08];0.5817
White blood count, x10 ⁹ /L	1.02[1.01-1.03];<0.0001***	1.02[1.00-1.05];0.1069	1.03[1.00-1.05];0.0187*	1.02[0.97-1.08];0.4938
Mean cell haemoglobin, pg	0.99[0.97-1.01];0.2267	1.01[0.97-1.05];0.6190	0.96[0.94-0.99];0.0133*	1.05[0.97-1.14];0.1981
Myelocyte, x10 ⁹ /L	0.93[0.84-1.02];0.1131	0.88[0.66-1.18];0.3893	0.83[0.66-1.04];0.1098	0.83[0.50-1.39];0.4823
Platelet, x10 ⁹ /L	1.001[1.000-1.001];0.0388*	1.001[1.000-1.002];0.2819	1.002[1.001-1.003];0.0015**	1.002[0.999-1.004];0.1452
Red blood count, x10 ¹² /L	0.93[0.86-1.01];0.0818	0.93[0.78-1.10];0.3688	0.91[0.79-1.06];0.2409	1.26[0.89-1.78];0.1925
Hematocrit, L/L	0.30[0.11-0.80];0.0163*	0.75[0.09-6.67];0.7997	0.18[0.03-1.13];0.0671	566.25[4.88-65751.46];0.0090**
Renal and liver functions				
Potassium, mmol/L	0.91[0.80-1.03];0.1211	1.03[0.79-1.35];0.8120	0.87[0.69-1.09];0.2157	0.92[0.56-1.52];0.7440
Urate, mmol/L	1.54[0.72-3.30];0.2671	5.04[0.95-26.62];0.0570	1.71[0.32-9.18];0.5314	0.65[0.02-19.52];0.8040
Albumin, g/L	0.97[0.96-0.98];<0.0001***	0.98[0.96-1.00];0.0540	0.98[0.96-0.99];0.0061**	1.04[0.99-1.09];0.1011
Sodium, mmol/L	0.97[0.96-0.98];<0.0001***	0.97[0.95-1.00];0.0227*	0.95[0.92-0.97];0.0001***	0.97[0.91-1.05];0.4786
Urea, mmol/L	0.99[0.97-1.02];0.5540	1.02[0.98-1.06];0.4164	0.98[0.93-1.03];0.4672	1.00[0.89-1.13];0.9939
Protein, g/L	0.99[0.99-1.00];0.0001***	1.00[0.99-1.01];0.8901	0.99[0.99-1.00];0.0087**	1.00[0.98-1.02];0.9227
Bilirubin, umol/L	1.003[1.002-1.005];<0.0001***	1.00[1.00-1.01];0.5730	1.00[1.00-1.01];0.9330	1.00[0.99-1.01];0.9730
Creatinine, umol/L	1.001[1.000-1.001];0.2210	1.000[0.998-1.002];0.7707	1.001[0.999-1.002];0.2969	1.00[0.99-1.00];0.4195
SD of creatinine	1.001[1.000-1.001];0.0001***	1.001[1.000-1.002];0.0719	1.001[1.000-1.001];0.0974	1.000[0.998-1.002];0.7760
Aspartate transaminase, U/L	1.001[1.001-1.001];<0.0001***	1.000[0.998-1.002];0.8846	1.001[0.999-1.002];0.4383	0.99[0.98-1.01];0.2798
SD of aspartate transaminase	1.001[1.000-1.001];<0.0001***	1.000[1.000-1.001];0.2117	1.001[1.000-1.002];0.0155*	1.001[0.997-1.004];0.6500
Alkaline phosphatase, U/L	1.001[1.001-1.002];<0.0001***	1.000[0.999-1.002];0.7097	1.000[0.999-1.001];0.4551	1.00[0.99-1.00];0.2454
SD of alkaline phosphatase	1.002[1.002-1.003];<0.0001***	1.002[1.001-1.003];0.0014**	1.003[1.002-1.003];<0.0001***	1.002[1.000-1.004];0.0359*
Alanine transaminase, U/L	1.000[1.000-1.001];0.3737	1.000[0.998-1.002];0.8684	0.999[0.995-1.002];0.3897	0.99[0.98-1.00];0.0914
SD of alanine transaminase	1.001[1.001-1.002];<0.0001***	1.001[1.000-1.002];0.0177*	1.001[1.000-1.003];0.0741	1.00[0.99-1.00];0.5347

Table 3 (continued)

Characteristics	Before matching		After 1:2 matching	
	All-cause mortality HR [95% CI];P value	Composite outcome HR [95% CI];P value	All-cause mortality HR [95% CI];P value	Composite outcome HR [95% CI];P value
Lipid, iron, and calcium profile				
Total iron-binding capacity, L	1.00[0.98-1.02];0.9971	1.00[0.95-1.05];0.9678	0.99[0.95-1.04];0.7518	3.87[0.00-Inf];0.9993
VitaminB12, pmol/L	0.999[0.998-1.000];0.1739	1.00[0.99-1.00];0.1813	1.000[0.998-1.002];0.7853	1.00[0.99-1.01];0.8806
Folate, ng/mL	1.00[0.97-1.03];0.9877	1.04[0.97-1.12];0.2752	1.00[0.96-1.05];0.8835	1.04[0.95-1.14];0.3791
Ferritin, pmol/L	1.000[1.000-1.000];0.4438	1.000[1.000-1.000];0.3647	1.000[1.000-1.000];0.2525	1.000[1.000-1.001];0.1003
Calcium, mmol/L	0.64[0.39-1.06];0.0826	0.41[0.13-1.26];0.1212	0.91[0.36-2.28];0.8345	1.40[0.20-9.84];0.7350
SD of calcium	12.70[5.21-30.97];<0.0001***	2.10[0.13-34.34];0.6015	4.69[1.00-22.02];0.0499*	2.32[0.04-132.03];0.6840
Phosphate, mmol/L	0.83[0.59-1.18];0.3059	0.79[0.36-1.74];0.5548	0.98[0.50-1.90];0.9464	0.61[0.14-2.69];0.5115
SD of phosphate	5.97[3.23-11.04];<0.0001***	7.44[1.81-30.57];0.0054**	3.91[0.74-20.76];0.1098	18.22[0.41-815.46];0.1345
Glycemic and clotting profile				
Triglyceride, mmol/L	0.96[0.88-1.05];0.3264	0.74[0.56-0.99];0.0436*	0.90[0.78-1.04];0.1556	0.61[0.35-1.09];0.0933
SD of triglyceride	0.84[0.64-1.11];0.2196	0.20[0.04-1.02];0.0526	0.69[0.41-1.17];0.1655	0.54[0.08-3.53];0.5213
Glucose, mmol/L	1.02[0.99-1.04];0.1738	1.00[0.94-1.05];0.9179	0.99[0.95-1.03];0.5861	0.90[0.79-1.04];0.1558
SD of glucose	1.06[1.02-1.11];0.0032**	1.07[0.98-1.16];0.1337	1.07[1.00-1.14];0.0580	1.07[0.92-1.23];0.3816
High sensitive troponin-I, ng/L	1.000[1.000-1.000];0.9239	1.000[1.000-1.000];0.1181	1.000[1.000-1.000];0.9382	1.000[1.000-1.001];0.1785
SD of high sensitive troponin-I	1.000[1.000-1.000];0.7182	1.000[1.000-1.000];0.0044**	1.000[0.999-1.001];0.9978	1.000[1.000-1.001];0.2563
APTT, second	1.01[1.00-1.03];0.1426	0.98[0.93-1.03];0.3733	0.99[0.95-1.03];0.6325	0.98[0.89-1.08];0.6750
SD of APTT	1.05[1.02-1.08];0.0006***	0.99[0.90-1.10];0.8880	1.01[0.90-1.13];0.8927	1.10[0.86-1.42];0.4432
Lactate dehydrogenase, U/L	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.001];0.0165*	1.000[1.000-1.001];0.0001***	1.000[0.999-1.001];0.6208
SD of lactate dehydrogenase	1.000[1.000-1.000];<0.0001***	1.000[1.000-1.001];0.0229*	1.002[1.001-1.002];<0.0001***	1.002[1.000-1.003];0.0056**
Total cholesterol, mmol/L	0.98[0.90-1.07];0.6769	0.92[0.75-1.13];0.4335	1.05[0.90-1.22];0.5598	1.42[1.00-2.00];0.0490*
SD of total cholesterol	1.14[0.84-1.55];0.3905	0.93[0.42-2.07];0.8677	1.23[0.73-2.07];0.4394	2.73[0.81-9.19];0.1058
Low-density lipoprotein, mmol/L	1.00[0.90-1.11];0.9905	0.96[0.76-1.22];0.7514	1.14[0.96-1.37];0.1398	1.67[1.14-2.45];0.0091**
SD of low-density lipoprotein	1.22[0.84-1.78];0.2952	1.13[0.45-2.83];0.7919	1.66[0.77-3.55];0.1928	7.64[1.84-31.77];0.0051**
High-density lipoprotein, mmol/L	0.93[0.73-1.19];0.5774	1.27[0.77-2.11];0.3530	0.97[0.62-1.50];0.8772	1.96[0.82-4.71];0.1309
SD of high-density lipoprotein	2.42[0.85-6.87];0.0971	1.55[0.11-21.84];0.7461	1.32[0.19-9.12];0.7758	1.09[0.01-164.28];0.9719

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$; HR: Hazard ratio; CI: Confidence interval; APTT: applied partial thromboplastin test; PD-1: Programmed death 1 inhibitors; PD-L1: programmed death 1 ligand inhibitors


Sensitivity analysis

Supplementary Table 7 presented the adjusted hazard ratios (and 95% CIs) of PD-L1 vs. PD-1 with cause-specific and subdistribution hazard competing risk analysis models for new onset cardiac composite and mortality outcomes after 1:2 propensity score matching. Supplementary Table 8 presented the hazard ratios for associations of PD-L1 vs. PD-1 using Cox proportional hazard model for adverse new onset cardiac composite and mortality outcome in the 1:2 matched cohort, with half-year lag time. Supplementary Table 9 presented the risk of incident new onset cardiac composite and mortality

outcomes associated with treatment of PD-L1 vs. PD-1 with multiple matching adjustment approaches including propensity score stratification, high-dimensional propensity score matching, and propensity score matching with inverse probability of treatment weighting. The above analysis confirmed the protective effects of PD-L1 treatment over PD-1 treatment on new onset cardiac complications and mortality risks (HR<1, P value<0.05).

Prediction strength of subclinical inflammatory biomarkers

In the matched cohort, higher aspartate transaminase-to-alanine transaminase ratio (HR: 1.09, 95% CI: [1.04-1.14],




P value=0.0004) and higher monocyte-to-lymphocyte ratio (HR: 1.2, 95% CI: [1.02-1.43], P value=0.0305) were significantly associated with all-cause mortality. A higher urea-to-creatinine ratio (HR: 1.01, 95% CI: [1.00-1.01], P value=0.0007) was significantly associated with new onset cardiac composite outcome (Table 5). The boxplots of inflammatory biomarkers stratified by PD-1/PD-L1 inhibitor use and development of adverse outcomes are shown in Fig. 5.

Discussion

The main findings are that: (i) the incidence of cardiovascular complications after PD-1 or PD-L1 inhibitor use was 16% in this territory-wide cohort of Chinese patients from Hong Kong, (ii) multivariable Cox regression showed older age, a shorter average readmission interval

and a higher number of hospital admissions were significant predictors of cardiovascular complications and (iii) patients who developed cardiovascular complications had shorter average readmission interval and higher number of hospitalizations after treatment with PD-1/PD-L1 inhibitors.

Cardiac involvement in PD1 or PD-L1 inhibitors is variable, and can potentially affect the conduction system, myocardium or pericardium [17]. Thus, heart block [18], Takotsubo cardiomyopathy [19], myocarditis [20, 21] and pericarditis [22] have been reported. A meta-analysis performed in 2018 found that anti-PD-1/PD-L1-related fatalities were often from pneumonitis (333 [35%]), hepatitis (115 [22%]), and neurotoxic effects (50 [15%]). Combination PD-1/ cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) deaths were frequently from colitis






Fig. 4 Boxplots of significant laboratory examination variability stratified by PD-1/PD-L1 inhibitor use and development of the composite outcome in the matched cohort

Table 4 Comparisons of hospitalization characteristics before and after PD1/PD-L1 treatment in patients with new onset heart failure, acute myocardial infarction, atrial fibrillation, and atrial flutter

Hospitalization characteristics	Before matching		P value	After 1:1 matching		P value
	Before treatment Mean(SD);N or Count(%)	After treatment Mean(SD);N or Count(%)		Before treatment Mean(SD);N or Count(%)	After treatment Mean(SD);N or Count(%)	
Heart failure (N = 244)			Heart failure (N = 75)			
Average readmission interval between episodes, days	299.3(680.4);n = 202	45.5(95.9);n = 244	<0.0001***	358.6(922.4);n = 61	38.1(45.2);n = 75	<0.0001***
No. of episodes	8.8(7.4);n = 202	13.8(12.3);n = 244	<0.0001***	11.0(7.8);n = 61	12.9(9.5);n = 75	<0.0001***
Hospital stay, days	26.6(35.0);n = 202	40.6(36.0);n = 244	<0.0001***	33.7(38.8);n = 61	39.9(39.6);n = 75	<0.0001***
Acute myocardial infarction (N = 38)			Acute myocardial infarction (N = 8)			
Average readmission interval between episodes, days	498.3(1094.7);n = 32	42.1(53.5);n = 38	<0.0001***	1576.1(2728.8);n = 6	38.9(16.4);n = 8	<0.0001***
No. of episodes	6.4(5.7);n = 32	13.2(8.9);n = 38	<0.0001***	5.8(3.9);n = 6	17.4(11.6);n = 8	<0.0001***
Hospital stay, days	24.5(28.9);n = 32	34.3(30.4);n = 38	<0.0001***	11.5(6.4);n = 6	20.8(12.3);n = 8	<0.0001***
Atrial fibrillation (N = 54)			Atrial fibrillation (N = 8)			
Average readmission interval between episodes, days	383.9(905.9);n = 46	43.4(48.0);n = 54	<0.0001***	715.5(1861.5);n = 6	49.4(45.0);n = 8	<0.0001***
No. of episodes	9.2(8.8);n = 46	12.5(10.2);n = 54	<0.0001***	15.6(11.1);n = 6	9.0(5.0);n = 8	<0.0001***
Hospital stay, days	28.7(29.3);n = 46	43.6(54.6);n = 54	<0.0001***	30.4(27.5);n = 6	23.4(25.5);n = 8	<0.0001***
Atrial flutter (N = 6)			Atrial flutter (N = 2)			
Average readmission interval between episodes, days	190.2(175.8);n = 5	42.5(47.1);n = 6	<0.0001***	-	-	-
No. of episodes	3.8(2.2);n = 5	11.5(7.8);n = 6	<0.0001***	-	-	-
Hospital stay, days	28.0(32.5);n = 5	33.3(22.1);n = 6	<0.0001***	-	-	-

* for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001; PD-1: Programmed death 1 inhibitors; PD-L1: programmed death 1 ligand inhibitors

Table 5 Multivariable univariable Cox regression models for new onset cardiac complication outcome and all-cause mortality in the matched cohort

Model 1	All-cause mortality	Composite outcome
Characteristics	HR [95% CI];P value	HR [95% CI];P value
PD-L1 v.s. PD-1	0.80[0.64-0.99];0.0389*	0.34[0.18-0.64];0.0009***
PD-L1 expenditure, HKD	1.000[1.000-1.0001];<0.0001***	1.000[1.000-1.000];0.0592
Total PD-L1 dose amount, mg	1.000[1.000-1.000];0.0728	1.000[1.000-1.000];0.2615
PD-L1 inhibitors duration, days	1.00[0.99-1.001];<0.0001***	0.99[0.99-1.00];0.0301*
PD-1 expenditure, HKD	1.000[1.000-1.0001];<0.0001***	1.000[1.000-1.0001];0.0014**
Total PD-1 dose amount (mg)	1.000[1.000-1.0001];0.0005***	1.000[1.000-1.000];0.1100
PD-1 inhibitors duration, days	0.998[0.997-0.998];<0.0001***	0.998[0.997-0.999];0.0006***
Model 2	All-cause mortality	Composite outcome
Characteristics	HR [95% CI];P value	HR [95% CI];P value
PD-L1 v.s. PD-1	0.79[0.61-0.99];0.0366*	0.34[0.16-0.65];0.0009***
PD-L1 expenditure, HKD	1.000[1.000-1.0001];<0.0001***	1.000[1.000-1.000];0.0528
Total PD-L1 dose amount, mg	1.000[1.000-1.000];0.0740	1.000[1.000-1.000];0.2448
PD-L1 inhibitors duration, days	1.00[0.99-1.00];<0.0001***	0.99[0.99-1.00];0.0295*
PD-1 expenditure, HKD	1.000[1.000-1.0001];<0.0001***	1.000[1.000-1.0001];0.0012**
Total PD-1 dose amount (mg)	1.000[1.000-1.0001];0.0007***	1.000[1.000-1.000];0.1334
PD-1 inhibitors duration, days	0.998[0.997-0.998];<0.0001***	0.998[0.997-0.999];0.0007***
Model 3	All-cause mortality	Composite outcome
Characteristics	HR [95% CI];P value	HR [95% CI];P value
PD-L1 v.s. PD-1	0.81[0.64-0.98];0.0322*	0.33[0.18-0.63];0.0007***
PD-L1 expenditure, HKD	1.000[1.000-1.0001];<0.0001***	1.000[1.000-1.0001];0.0433*
Total PD-L1 dose amount, mg	1.000[1.000-1.000];0.0733	1.000[1.000-1.000];0.2482
PD-L1 inhibitors duration, days	1.00[1.00-1.001];<0.0001***	0.99[0.99-1.00];0.0282*
PD-1 expenditure, HKD	1.000[1.000-1.0001];<0.0001***	1.000[1.000-1.0001];0.0020**
Total PD-1 dose amount (mg)	1.000[1.000-1.0001];0.0008***	1.000[1.000-1.000];0.1673
PD-1 inhibitors duration, days	0.998[0.997-0.998];<0.0001***	0.998[0.997-0.999];0.0008***

Model 1 adjusted for significant demographics


Model 2 adjusted for significant demographics, and past comorbidities

Model 3 adjusted for significant demographics, past comorbidities, and non-PD-L1/PD-1 medications

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$; HR: Hazard ratio; CI: Confidence interval; APTT: applied partial thromboplastin test; PD-1: Programmed death 1 inhibitors; PD-L1: programmed death 1 ligand inhibitors; IR: incidence rate

(32 [37%]) and myocarditis (22 [25%]) [23]. In an analysis of the World Health Organization global database of adverse drug reactions in 2019, 2.1% of 106,025 patients receiving PD-1 or PD-L1 inhibitors had cardiovascular complications [9]. However, previous studies have largely been limited to case reports [18, 24], case series [25], single-center studies [26] or small registries [27, 28]. In this territory-wide study from Hong Kong, we found that cardiovascular complications occurred in 16% of all patients receiving PD-1 or PD-L1 inhibitors. Of these, the commonest is heart failure. Previously, acute heart failure has been described in the context of myocarditis [29], but heart failure without myocarditis has also been reported [30]. Our study also identified cases of acute myocardial infarction following the initiation of PD-1/PD-L1 inhibitor therapy. Such findings would be in keeping with coronary toxicity that has been reported in the context of PD-1 inhibitor therapy [27].

It is worth noting that the present study is the first to compare the cardiotoxicity between PD-1 and PD-L1 inhibitor treatment. The reason for the protective effect of PD-L1 inhibitor to be stronger than PD-1 inhibitor may be the stronger immune-mediated effects of PD-1 inhibitor. Contrary to PD-1 inhibitor, which blocks the interaction between PD-1 and both PD-L1 and PD-L2, PD-L1 inhibitor only blocks the interaction between PD-1 and PD-L1. [31] Although cancer may escape from immune-mediated detection via the PD-1/ PD-L2 axis under PD-L1 inhibitor treatment, it also implies that PD-L1 inhibitor may have weaker autoimmunity, thus resulting in less immune-mediated cardiotoxicity. [32] Furthermore, patients who developed cardiovascular complications had a shorter average readmission interval and more hospitalizations, which is due to the deterioration in patients' general health and treatment needed for the complications. For example, acute exacerbation



of heart failure is known to be common reasons for frequent admissions. The presence of adverse cardiovascular events is detrimental to the overall health of cancer patients who are already frail, which may lead to the decline in health and related frequent admissions, which demonstrates the critical effects of cardiovascular complications on patients' physical health and quality of life.

Interestingly, our study did not identify any patients with myocarditis after treatment with PD-1 or PD-L1 inhibitors. Moreover, within the excluded patients with prior cardiovascular complications, none developed subsequent myocarditis. In 964 patients attending Massachusetts General Hospital, the incidence of myocarditis was 1.1% (n=35) [28]. In this cohort, myocarditis was more frequently observed in patients with pre-existing cardiovascular comorbidities. Nevertheless, another study using the VigiBase database found 101 cases of severe myocarditis, of which 75% of the myocarditis cases did not have pre-existing cardiovascular disease [33]. A single-center study of 283 patients from China found only 3 cases (1.1%) of myocarditis, with variable presentations such as palpitations, dyspnea, and fatigue, or asymptomatic with

incidental finding of grade 3 atrioventricular block and premature ventricular complexes on the electrocardiogram [26]. In a pooled, retrospective review of three trials including 448 patients with advanced melanoma receiving PD-1/PD-L1 inhibitor therapy, no cases of myocarditis were identified [34]. In association with myocarditis, different investigators have reported the presence of conduction abnormalities in the form of atrioventricular block [18, 25, 26, 35].

Limitations

There are some limitations of this study that should be acknowledged. Firstly, this was an administrative database study, and therefore cancer staging details could not be extracted. Secondly, under-coding or miscoding remains a possibility as with studies of a similar nature. Thirdly, although no cases of myocarditis were found. As our study relies on ICD-9 coding, this might be due to under-coding. Alternatively, missed cases by the clinicians and subclinical myocarditis leading to heart failure are possible. Therefore, further studies accounting for parameters that may uncover undiagnosed

myocarditis, such as creatine kinase, is needed to ensure that the diagnosis of myocarditis is not missed.

Conclusions

Compared with PD-1 inhibitor use, PD-L1 inhibitor use was significantly associated with lower risks of cardiac complications and all-cause mortality both before and after propensity score matching. Patients who developed cardiovascular complications had shorter average readmission intervals and a higher number of hospitalizations after treatment with PD-1/PD-L1 inhibitors.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40959-021-00128-5>.

Additional file 1.

Acknowledgements

None.

Authors' contributions

JZ, SL, GT: data analysis, data interpretation, statistical analysis, manuscript drafting, critical revision of manuscript. IL, SL, LY, TL, YX, YZ: data interpretation, manuscript drafting. EWC, ICKW: project planning, data acquisition, data interpretation, critical revision of manuscript. QZ: study conception, study supervision, project planning, data interpretation, statistical analysis, manuscript drafting, critical revision of manuscript. The author(s) read and approved the final manuscript.

Authors' information

None.

Funding

None.

Availability of data and materials

Data availability upon request to the corresponding author.

Declarations

Ethics approval and consent to participate

This study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee. The need for informed consent was waived by the Ethics Committee owing to the retrospective and observational nature of the study.

Consent for publication

N/A.

Competing interests

None.

Author details

¹Nuffield Department of Medicine, University of Oxford, Oxford, UK. ²Cardio-Oncology Research Unit, Cardiovascular Analytics Group, UK Collaboration, Hong Kong, China. ³Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, 300211 Tianjin, China. ⁴Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ⁵Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

⁶School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China.

⁷Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China. ⁸Department of Pharmacology and Pharmacy, University of Hong Kong, Pokfulam, Hong Kong, China. ⁹Kent and Medway Medical School, Canterbury, UK. ¹⁰School of Data Science, City University of Hong Kong, Hong Kong, China.

Received: 19 August 2021 Accepted: 20 December 2021

Published online: 17 March 2022

References

- Boussiottis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. *N Engl J Med*. 2016;375:1767–78.
- Kalinich M, Murphy W, Wongvibulsin S, et al. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. *J Immunother Cancer* 2021;9.
- Griewing LM, Schweizer C, Schubert P, et al. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. *BMC Cancer*. 2021;21:314.
- Wu C, Zhong L, Wu Q, Lin S, Xie X. The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. *Immunotherapy*. 2021;13:527–39.
- Kang JH, Bluestone JA, Young A. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. *Trends Immunol*. 2021;42:293–311.
- Lee S, Tse G. A Patient with Atezolizumab-Induced Autoimmune Diabetes Mellitus Presenting with Diabetic Ketoacidosis. *Cardiovascular Innovations and Applications*; 2021.
- Zhang N, Tse G, Liu T. Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis. *Eur Heart J* 2021.
- Ball S, Ghosh RK, Wongsangsak S, et al. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019;74:1714–27.
- Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. *Chronic Dis Transl Med*. 2019;5:6–14.
- Muller OJ, Spehlmann ME, Frey N. Cardio-toxicity of checkpoint inhibitors. *J Thorac Dis*. 2018;10:4400–4.
- Lee S, Zhou J, Guo CL, et al. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. *Endocrinol Diabetes Metab*. 2021;4:e00240.
- Tse G, Zhou J, Lee S, et al. Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. *J Hypertens*. 2021;39:1717–24.
- Lee S, Zhou J, Leung KSK, et al. Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong. *BMJ Open Diabetes Res Care* 2021;9.
- Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariable Behav Res*. 2011;46:399–424.
- Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med*. 2015;34:3661–79.
- Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology*. 2009;20:512–22.
- Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncol*. 2018;19:e447–58.
- Khan A, Riaz S, Carhart R. Jr. Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. *Case Rep Cardiol*. 2020;2020:8428210.
- Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. *J Immunother Cancer*. 2015;3:4.
- Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. *J Immunother Cancer*. 2017;5:91.
- Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C. Drug-induced myocarditis after nivolumab treatment in a patient with

- PDL1- negative squamous cell carcinoma of the lung. *Lung Cancer*. 2016;99:117–9.
22. de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy. *J Immunother*. 2018;41:329–31.
 23. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018;4:1721–8.
 24. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N Engl J Med*. 2016;375:1749–55.
 25. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. *J Immunother Cancer*. 2016;4:50.
 26. Wang F, Sun X, Qin S, et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. *Chin Clin Oncol*. 2020;9:16.
 27. Ferreira M, Pichon E, Carmier D, et al. Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. *Target Oncol*. 2018;13:509–15.
 28. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. *J Am Coll Cardiol*. 2018;71:1755–64.
 29. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. *J Immunother Cancer*. 2015;3:11.
 30. Chauhan A, Burkeen G, Houranieh J, Arnold S, Anthony L. Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature. *Ann Oncol*. 2017;28:2034–8.
 31. Duan J, Cui L, Zhao X, et al. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2020;6:375–84.
 32. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. *J Clin Invest*. 2015;125:3384–91.
 33. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *Lancet*. 2018;391:933.
 34. Sznol M, Ferrucci PF, Hogg D, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. *J Clin Oncol*. 2017;35:3815–22.
 35. Lopez EM, Dunn S, Mazimba S. MALIGNANT ARRHYTHMIAS IN, AUTOIMMUNE MYOCARDITIS SECONDARY TO IMMUNE CHECKPOINT BLOCKADE TREATMENT. *J Am Coll Cardiol*. 2018;71:A2375.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.